Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Frank KroschinskyJan Moritz MiddekeMartin JanzGeorg LenzMathias Witzens-HarigReda BouabdallahPaul La RoséeAndreas ViardotGilles SallesSeok Jin KimTae Min KimOliver OttmannJoerg ChromikAnne-Marie QuinsonUte von WangenheimUte BurkardAndreas BerkNorbert SchmitzPublished in: Investigational new drugs (2020)
The article Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Keyphrases